Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis

 Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis

Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis

Shots:

  • The P-III OPTIMUM study involves assessing of Ponesimod (20 mg) vs Aubagio (teriflunomide, 14mg) in 1,133 patients with relapsing multiple sclerosis for 108 weeks
  • The study resulted in meeting 1 EPs of annualized relapse rate (ARR) up to the end of the study and most of its 2 EPs with no new observed signals
  • Ponesimod is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, inhibiting S1P activity and reduces the number of circulating lymphocytes with its anticipated EMA’s approval for relapsing MS in H2’19

Click here to­ read full press release/ article | Ref: Janssen| Image: Opthalmology Innovation Summit

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post